Literature DB >> 2212370

The automatic implantable cardioverter-defibrillator in young patients.

J Kron1, R P Oliver, S Norsted, M J Silka.   

Abstract

An international survey identified 40 patients less than 20 years old who underwent surgical implantation of an automatic implantable cardioverter-defibrillator (AICD). There was a history of aborted sudden cardiac death or sustained ventricular tachycardia in 92.5% of these patients. Twenty-two patients (55%) had structural heart disease; dilated and hypertrophic cardiomyopathy were the most common diagnoses. Eighteen patients (45%) had primary electrical abnormalities including seven with the congenital long QT syndrome. There were no perioperative deaths associated with device implantation. Concomitant drug therapy was administered to 75% of the patients. Defibrillator discharge occurred in 70% of the patients, with 17 patients (42.5%) receiving at least one appropriate shock. There were two sudden and two nonsudden deaths at 28.2 months' median follow-up. Sudden death-free survival rates by life table analysis at 12 and 33 months were 0.94 and 0.88, respectively. Total survival rates at 12 and 33 months were 0.94 and 0.82, respectively. The AICD represents an effective treatment approach for young patients with life-threatening ventricular tachyarrhythmias.

Entities:  

Mesh:

Year:  1990        PMID: 2212370     DOI: 10.1016/s0735-1097(10)80338-9

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  9 in total

1.  Implantable cardioverter defibrillator implantation in children in The Netherlands.

Authors:  A Derk Jan Ten Harkel; Nico A Blom; Annette G Reimer; Raymond Tukkie; Narayanswami Sreeram; Margreet T E Bink-Boelkens
Journal:  Eur J Pediatr       Date:  2005-04-21       Impact factor: 3.183

2.  Supraventricular tachyarrhythmias, congenital heart disease, and sudden cardiac death.

Authors:  M Silka; J Kron; J McAnulty
Journal:  Pediatr Cardiol       Date:  1992-04       Impact factor: 1.655

Review 3.  Hypertrophic cardiomyopathy: management issues in the new millennium.

Authors:  Rajesh Thaman; Sami Firoozi; M S Hamid; William J McKenna
Journal:  Curr Cardiol Rep       Date:  2002-05       Impact factor: 2.931

Review 4.  The role of pharmacologic treatment to prevent sudden death in the implantable cardioverter defibrillator era.

Authors:  P M Elliott
Journal:  Curr Cardiol Rep       Date:  2001-03       Impact factor: 2.931

5.  Cardiac dysrhythmias in children with idiopathic dilated or hypertrophic cardiomyopathy.

Authors:  G Müller; H E Ulmer; K J Hagel; D Wolf
Journal:  Pediatr Cardiol       Date:  1995 Mar-Apr       Impact factor: 1.655

6.  Perinatal manifestations of idiopathic long QT syndrome.

Authors:  C J Mache; A Beitzke; M Haidvogl; A Gamillscheg; C Suppan; J I Stein
Journal:  Pediatr Cardiol       Date:  1996 Mar-Apr       Impact factor: 1.655

Review 7.  New antiarrhythmic drugs in pediatric use: amiodarone.

Authors:  T Paul; P Guccione
Journal:  Pediatr Cardiol       Date:  1994 May-Jun       Impact factor: 1.655

8.  Implantable cardioverter defibrillator therapy in children with long QT syndrome.

Authors:  A K Goel; S Berger; A Pelech; A Dhala
Journal:  Pediatr Cardiol       Date:  2004 Jul-Aug       Impact factor: 1.655

9.  Implantable cardioverter defibrillator therapy for life-threatening arrhythmias in young patients.

Authors:  Christopher B Stefanelli; David J Bradley; Sarah Leroy; Macdonald Dick; Gerald A Serwer; Peter S Fischbach
Journal:  J Interv Card Electrophysiol       Date:  2002-07       Impact factor: 1.900

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.